Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Rev. biol. trop ; 56(4): 1635-1643, Dec. 2008. tab
Artigo em Inglês | LILACS | ID: lil-637768

RESUMO

Onchocerciasis is an endemic disease in Ondo state, Nigeria. Community directed distribution of ivermectin is currently on-going in some local government areas of the state. Randomly selected persons (2 331 males and 2 469 females) were interviewed using a modified rapid assessment procedure for Loa loa (RAPLOA) to assess community directed treatment with ivermectin. The retrospective study evaluated the coverage, impacts and adverse reactions to the drug treatment. A questionnaire was administered by house-to-house visit in six local government areas, implementing community directed treatment with ivermectin (CDTI) in this bioclimatic zone. A total of 2,398 respondents were reported to have participated in the treatment. The overall ivermectin coverage of 49.96% was recorded (range 0 - 52% in different communities). Adverse reactions from ivermectin administration were experienced in 38% of individuals. Diverse adverse reactions experienced included predominantly itching (18.50%); oedema, especially of the face and the limbs (8.2%); rashes (3.4%) and body weakness (2.4%). Expulsion of intestinal worms occurred in 0.96% of the respondents. The occurrence of adverse reactions in relation to age categories was statistically significant. Neither fatal nor severe adverse reactions were reported by respondents. Significantly, despite experienced adverse reactions, continued participation, acceptability and compliance to ivermectin treatment was expressed by the various communities. This attitude is in consonance with the African Programme for Onchocerciasis Control (APOC) objectives. Rev. Biol. Trop. 56 (4): 1635-1643. Epub 2008 December 12.


La oncocercosis es endémica en el estado Ondo, Nigeria. Se seleccionaron 4 800 personas al azar para evaluar con encuesta retrospectiva la cobertura, efectos y reacciones al tratamiento farmacológico con ivermectina administrado por la misma comunidad. La cobertura global de ivermectina fue 50 % con reacciones adversas en 38 % de los individuos. Estas fueron comezón picazón (18%), edema, especialmente de la cara y las extremidades (8%), erupciones cutáneas (3%) y debilidad (2%); dependieron de la edad y no hubo reacciones más graves. La expulsión de las lombrices intestinales se produjo en 96% de los encuestados. A pesar de las reacciones adversas, hubo continuidad, aceptación y cumplimiento del tratamiento con ivermectina, en consonancia con los objetivos del Programa Africano para el Control de Oncocercosis (APOC).


Assuntos
Adolescente , Adulto , Idoso , Animais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem , Antiparasitários/efeitos adversos , Doenças Endêmicas/prevenção & controle , Ivermectina/efeitos adversos , Loíase/tratamento farmacológico , Oncocercose/tratamento farmacológico , Antiparasitários/uso terapêutico , Ivermectina/uso terapêutico , Loíase/epidemiologia , Loíase/prevenção & controle , Programas Nacionais de Saúde , Nigéria/epidemiologia , Oncocercose/epidemiologia , Oncocercose/prevenção & controle , Estudos Retrospectivos
2.
Ann Trop Med Parasitol ; 102(3): 215-27, 2008 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-18348776

RESUMO

The rapid assessment procedure for loiasis (RAPLOA) was used to assess the prevalences of loiasis among 4800 subjects in 60 villages in Ondo state, south-western Nigeria. Coverages for community-directed treatment with ivermectin (CDTI) were assessed in the same communities, which were located in the Owo, Akure North, Ifedore, Akure South, Ondo East and Ondo West local government areas (LGA). In addition, fingerprick blood samples were collected from 80 individuals in each of six villages (i.e. one village in each LGA investigated) and checked for Loa loa microfilaraemia. Microfilaraemias were only detected in three of the villages where blood samples were collected and then only at low prevalences (1.25%-5.0%) and intensities (267-1600 microfilariae/ml). No serious adverse events were or ever had been related to the CDTI but mild or moderate adverse reactions were quite common, especially in Akure North (55.0%) and Owo (40.2%). A female subject was more likely to report an history of eye worm than a male subject (20.3%-35.7% v. 20.8%-26.5%, according to LGA). Although the subjects aged 41-50 years formed the age-group most likely to report an history of eye worm (32.7%), the highest CDTI coverage was recorded in the subjects aged 61-70 years (54.7%). The results indicated that CDTI had helped to reduce the prevalence and intensity of Loa microfilaraemia and that ivermectin can continue to be used for mass administrations in Ondo state with little risk of serious adverse events.


Assuntos
Doenças Endêmicas , Loíase/epidemiologia , Adulto , Idoso , Animais , Feminino , Filaricidas/uso terapêutico , Humanos , Ivermectina/uso terapêutico , Loíase/diagnóstico , Loíase/tratamento farmacológico , Masculino , Programas de Rastreamento/métodos , Pessoa de Meia-Idade , Nigéria/epidemiologia , Oncocercose/tratamento farmacológico , Prevalência
3.
Rev Biol Trop ; 56(4): 1635-43, 2008 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-19419072

RESUMO

Onchocerciasis is an endemic disease in Ondo state, Nigeria. Community directed distribution of ivermectin is currently on-going in some local government areas of the state. Randomly selected persons (2331 males and 2469 females) were interviewed using a modified rapid assessment procedure for Loa loa (RAPLOA) to assess community directed treatment with ivermectin. The retrospective study evaluated the coverage, impacts and adverse reactions to the drug treatment. A questionnaire was administered by house-to-house visit in six local government areas, implementing community directed treatment with ivermectin (CDTI) in this bioclimatic zone. A total of 2,398 respondents were reported to have participated in the treatment. The overall ivermectin coverage of 49.96% was recorded (range 0-52% in different communities). Adverse reactions from ivermectin administration were experienced in 38% of individuals. Diverse adverse reactions experienced included predominantly itching (18.50%); oedema, especially of the face and the limbs (8.2%); rashes (3.4%) and body weakness (2.4%). Expulsion of intestinal worms occurred in 0.96% of the respondents. The occurrence of adverse reactions in relation to age categories was statistically significant. Neither fatal nor severe adverse reactions were reported by respondents. Significantly, despite experienced adverse reactions, continued participation, acceptability and compliance to ivermectin treatment was expressed by the various communities. This attitude is in consonance with the African Programme for Onchocerciasis Control (APOC) objectives. Rev. Biol.


Assuntos
Antiparasitários/efeitos adversos , Doenças Endêmicas/prevenção & controle , Ivermectina/efeitos adversos , Loíase/tratamento farmacológico , Oncocercose/tratamento farmacológico , Adolescente , Adulto , Idoso , Animais , Antiparasitários/uso terapêutico , Feminino , Humanos , Ivermectina/uso terapêutico , Loíase/epidemiologia , Loíase/prevenção & controle , Masculino , Pessoa de Meia-Idade , Programas Nacionais de Saúde , Nigéria/epidemiologia , Oncocercose/epidemiologia , Oncocercose/prevenção & controle , Estudos Retrospectivos , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...